【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】智通財經

智通財經

2025/07/04

【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】智通財經APP訊，基石藥業-B(02616.HK)公布有關CS1003-305研究的最新進展，CS1003-305研究是一項國際多中心、雙盲、隨機對照的III期註冊研究，在全球範圍內設有74家研究中心，旨在評估PD-1單抗nofazinlimab(CS1003)聯合侖伐替尼對比安慰劑聯合侖伐替尼一線治療不可切除或轉移性肝細胞癌(HCC)患者的有效性和安全性。該研究的主要終點為總生存期(OS)。關鍵次要終點包括盲態獨立中心審閱(BICR)評估的無進展生存期(PFS)和客觀緩解率(ORR)。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548394331"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548394331\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548394331?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-04 22:34","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2548394331","market":"hk","top_or_hot":-1,"title":"【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】智通財經","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】</b>智通財經APP訊，基石藥業-B(02616.HK)公布有關CS1003-305研究的最新進展，CS1003-305研究是一項國際多中心、雙盲、隨機對照的III期註冊研究，在全球範圍內設有74家研究中心，旨在評估PD-1單抗nofazinlimab(CS1003)聯合侖伐替尼對比安慰劑聯合侖伐替尼一線治療不可切除或轉移性肝細胞癌(HCC)患者的有效性和安全性。該研究的主要終點為總生存期(OS)。關鍵次要終點包括盲態獨立中心審閱(BICR)評估的無進展生存期(PFS)和客觀緩解率(ORR)。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】智通財經</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】智通財經\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-07-04 22:34</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】</b>智通財經APP訊，基石藥業-B(02616.HK)公布有關CS1003-305研究的最新進展，CS1003-305研究是一項國際多中心、雙盲、隨機對照的III期註冊研究，在全球範圍內設有74家研究中心，旨在評估PD-1單抗nofazinlimab(CS1003)聯合侖伐替尼對比安慰劑聯合侖伐替尼一線治療不可切除或轉移性肝細胞癌(HCC)患者的有效性和安全性。該研究的主要終點為總生存期(OS)。關鍵次要終點包括盲態獨立中心審閱(BICR)評估的無進展生存期(PFS)和客觀緩解率(ORR)。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7095","symbol_name":"多種金屬與採礦","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2548394331","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548394331","pubTimestamp":1751639654,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】智通財經APP訊，基石藥業-B(02616.HK)公布有關CS1003-305研究的最新","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK7095":"多种金属与采矿","02616":"基石药业-B","BK4006":"钢铁","PD":"PagerDuty, Inc.","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","HCC":"Warrior Met Coal LLC","ORR.AU":"ORECORP LTD","OS":"OneStream, Inc.","BK4134":"信息科技咨询与其它服务","BK4211":"区域性银行","BK1161":"生物科技","III":"信息服务","BK4097":"系统软件","BK4023":"应用软件","BK4195":"互助储蓄与抵押信贷金融服务","PFS":"Provident Financial Services Inc","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","ORR":"Militia Long/Short Equity ETF","BK1574":"生物医药B类股"},"translate_title":"[CStone Pharmaceuticals-B (02616. HK) announces the latest progress of the international multi-center phase III study of Nofazinlimab in the treatment of hepatocellular carcinoma] Zhitong Finance","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORR.AU":1,"OS":1,"ORR":1,"HCC":1,"III":1,"02616":1,"PD":1,"PFS":1},"content_text":"【基石藥業-B(02616.HK)公布Nofazinlimab治療肝細胞癌的國際多中心 III期研究的最新進展】智通財經APP訊，基石藥業-B(02616.HK)公布有關CS1003-305研究的最新進展，CS1003-305研究是一項國際多中心、雙盲、隨機對照的III期註冊研究，在全球範圍內設有74家研究中心，旨在評估PD-1單抗nofazinlimab(CS1003)聯合侖伐替尼對比安慰劑聯合侖伐替尼一線治療不可切除或轉移性肝細胞癌(HCC)患者的有效性和安全性。該研究的主要終點為總生存期(OS)。關鍵次要終點包括盲態獨立中心審閲(BICR)評估的無進展生存期(PFS)和客觀緩解率(ORR)。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}